AbbVie – Page 4

Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar

1 year ago talkbio0Tagged AbbVie, adjunctive therapy, Antipsychotic Agents, Approved, Caplyta, Clinical Trials, Depressive disorder, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, United States Food and Drug Administration, Vraylar

Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials

Top 10 Pharmaceutical Drug Ad Spenders: A Review of the Latest Rankings

1 year ago talkbio0Tagged AbbVie, Caplyta, Drugs, Non-Prescription, Dupixent, Jardiance, Opdivo, Rexulti, Rinvoq, Sotyktu, Vraylar

pharmaceutical drug ad spenders, top 10, AbbVie, Skyrizi, Rexulti, Dupixent, Rinvoq, Vraylar, Sotyktu, Jardiance, Ozempic, Caplyta, Opdivo

AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success

1 year ago talkbio0Tagged AbbVie, Antibody-Drug Conjugates, Antigens, Elahere, ovarian neoplasm, Phase 2 Clinical Trials, Return on Investment, ROI

AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere

ASCO: AbbVie Revamps ADC Portfolio to Replace Chemotherapy

1 year ago talkbio0Tagged AbbVie, ADCs, ASCO, Malignant Neoplasms, Pharmacotherapy, Rova-T, Teliso-V

ASCO, AbbVie, ADCs, Chemotherapy, Rova-T, Teliso-V, Cancer Treatment

AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment

1 year ago talkbio0Tagged AbbVie, Acquisition (action), Antibody-Drug Conjugates, Antigens, Clinical Trials, Elahere, Neoplasms, ovarian neoplasm

AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology

AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership

1 year ago talkbio0Tagged AbbVie, Drug Development, Gilgamesh, Hallucinogens, Mental disorders, mental health, Neuroscience discipline, next-generation

AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.